Insurance status is related to diffuse large B-cell lymphoma survival

By Han Xuesong   Jemal Ahmedin   Flowers Christopher R.   Sineshaw Helmneh   Nastoupil Loretta J.   Ward Elizabeth  

Cancer, Vol. 120, Iss. 8, 2014-04 ,pp. : 1220-1227

Blackwell Publishing

Access to resources Recommend Favorite

Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin’s lymphoma: a consortium for improving survival of lymphoma (CISL) trial

By Park Byeong-Bae   Kim Won   Eom Hyeon   Kim Jin   Lee Young   Oh Suk   Lee Dae   Suh Cheolwon  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 154-160

Springer Publishing Company

Access to resources Recommend Favorite

Characteristics of primary splenic diffuse large B-cell lymphoma and role of splenectomy in improving survival

By  

Cancer, Vol. 121, Iss. 17, 2015-09 ,pp. : 2909-2916

Blackwell Publishing

Access to resources Recommend Favorite

Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma

By Williams Jessica N.   Rai Ashish   Lipscomb Joseph   Koff Jean L.   Nastoupil Loretta J.   Flowers Christopher R.  

Cancer, Vol. 121, Iss. 11, 2015-06 ,pp. : 1800-1808

Blackwell Publishing

Access to resources Recommend Favorite

Response and survival benefit with chemoimmunotherapy in Epstein‐Barr virus‐positive diffuse large B‐cell lymphoma

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 93-97

John Wiley & Sons Inc

Access to resources Recommend Favorite